SELDI-TOF MS 技术在免疫耗竭血清中用于胰腺癌诊断生物标志物的发现。

Discovery of diagnostic biomarkers for pancreatic cancer in immunodepleted serum by SELDI-TOF MS.

机构信息

Department of Surgery, The University of Sydney, Suite 5 Level 5 North Shore Private Hospital, St Leonards, NSW 2065 Australia.

出版信息

Pancreatology. 2012 Mar-Apr;12(2):124-9. doi: 10.1016/j.pan.2012.02.009. Epub 2012 Feb 21.

DOI:10.1016/j.pan.2012.02.009

PMID:22487522

Abstract

MOTIVATION

Reports of serum pancreatic cancer (PC) biomarkers using SELDI-TOF MS have been inconsistent because different chip surfaces and interference with high-abundant proteins. This study examines the influence of these factors on the detection of discriminating diagnostic biomarkers.

METHODS

Serum from fourteen from patients with PC, disease controls (DC, n = 14) and healthy volunteers (HV, n = 14) were evaluated by SELDI using H50, IMAC, Q10 and CM10 chips. A further evaluation was undertaken after depletion of seven high-abundant proteins using spin cartridges.

RESULTS

More protein peaks were detected in whole serum than in depleted serum for IMAC, H50 and Q10 chips: 60 vs 39, 56 vs 48 and 69 vs 65, respectively, while the CM10 found less peaks in serum (27 vs 47 peaks). However, there were more differentially expressed peaks in the depleted serum samples for PC vs DC and PC vs HV samples using the H50, Q10 and CM10 ProteinChip arrays, whereas for IMAC arrays, more discriminating peaks were seen in non-depleted serum. The highly significant peaks observed on Q10, CM10 and H50 are consistent with the previous finding of ApoA-I (m/z 27,910-28000) and ApoA-II (m/z 8758 and 17,240). In addition, a number of new discriminating protein peaks were found on different ProteinChip arrays, notably peaks at m/z 4280 and 7763 on IMAC arrays.

CONCLUSION

This study confirms the diagnostic value of ApoA-I&II and identifies further potential diagnostic biomarkers for pancreatic cancer when multiple chip surfaces are used with depletion of the most highly-abundant proteins.

摘要

动机

使用 SELDI-TOF MS 报道的血清胰腺癌 (PC) 生物标志物结果并不一致，这是由于不同的芯片表面和与高丰度蛋白的干扰。本研究探讨了这些因素对检测有区别的诊断生物标志物的影响。

方法

用 SELDI 技术检测了 14 例 PC 患者、疾病对照组（DC，n=14）和健康志愿者（HV，n=14）的血清，分别使用 H50、IMAC、Q10 和 CM10 芯片。在使用旋转柱去除七种高丰度蛋白后，对其进行了进一步评估。

结果

与非去蛋白血清相比，IMAC、H50 和 Q10 芯片在去蛋白血清中检测到更多的蛋白峰：分别为 60 个对 39 个、56 个对 48 个和 69 个对 65 个，而 CM10 在血清中发现的峰较少（27 个对 47 个峰）。然而，在 H50、Q10 和 CM10 蛋白芯片阵列中，PC 与 DC 和 PC 与 HV 样本相比，去蛋白血清样本中差异表达的峰更多，而在 IMAC 阵列中，未去蛋白血清中观察到更多的区分峰。在 Q10、CM10 和 H50 上观察到的高度显著峰与先前发现的 ApoA-I（m/z 27910-28000）和 ApoA-II（m/z 8758 和 17240）一致。此外，在不同的蛋白芯片阵列上还发现了一些新的有区别的蛋白峰，特别是在 IMAC 阵列上的 m/z 4280 和 7763 峰。